Dr Read is the Executive Chairman at Global Kinetics and Venture Partner at Brandon Capital. He is an American serial entrepreneur and venture investor with a track record of building successful companies across the range of life-science technologies. He was previously a managing director of Alloy Ventures and before that had co-founded Affymax NV (acquired by GSK, was the founding investor, Chairman and CEO of Aviron the company that developed FluMist acquired by MedImmune) and Avidia (acquired by Amgen). Leighton has a Bachelor of Science from Rice University and an MD from the University of Texas Health Science Center. He completed internal medicine training at Duke and the Peter Bent Brigham Hospital, where he held appointments at the Harvard Medical School and School of Public Health publishing in the fields of decision and cost-effectiveness analysis. Leighton is currently a director of EBR Systems, Foundry Therapeutics 1 Okogen and Glyscend. He is also a director of BioVentures for Global Health.
Anna is a seasoned finance executive with over 25 years of experience in financial reporting, management and analysis across a wide range of industries including Fin Tech, Biotech, Banking and Finance and Import/Distribution in public, private and government arenas. Her previous roles include Chief Financial Officer and Company Secretary at an ASX listed biotech, Financial Analyst at Australia Post and Associate Director at BZW Australia. Anna has B.Econ from Macquarie University, Dip Law from Legal Practitioners Admission Board (NSW), Graduate Diploma in Applied Corporate Governance and is a Fellow of the Governance Institute of Australia.
Dr. Nahab is a board-certified Movement Disorders Neurologist with an interest and track record of bridging the gaps between Neurology and technology. His research background began at in the Human Motor Control laboratory within the National Institutes of Health in Bethesda, Maryland. Since that time, Fatta has conducted NIH-funded neuroimaging research into the mechanisms underlying tremor, novel investigator-initiated phase I/II clinical trials, clinical research in disorders such as Parkinson’s disease and essential tremor while also helping to lead international efforts to develop and integrate objective measures into patient management in order to enhance care. Fatta is also the author of numerous peer-reviewed publications, book chapters, and scientific abstracts in both national and international venues.
Neil has more than 20 years’ experience in the pharmaceutical and health care industry and has held leadership roles in sales, marketing and market development, working for Eli Lilly Ltd and Medtronic Ltd. Neil has also lead change management programs and consultancy assignments with Bain and Boston Consulting. Neil has extensive experience working within the NHS in the UK and several years’ experience driving European markets. Neil has successfully launched remote management technologies for the management of implantable cardiac devices, whilst navigating reimbursement and driving execution to achieve sales performance in deep brain stimulation, for Parkinson’s disease.
James Quackenbush has served as Vice President of Operations since January 2020. Prior to joining GKC, James spent over thirty years working in the medical device industry. Most recently as COO/CEO of Medspira LLC, a start-up medical device company, were he developed a novel portable manometry device for diagnosing and treating fecal incontinence. From 1999 through 2010 James served as Vice President of Manufacturing for Vascular Solutions Incorporated later acquired by Teleflex. From 1992 through 1999, James served as Vice President of Manufacturing and Operations for Optical Sensors Incorporated, a diagnostic medical device company. Before those engagements he served as Operations Manager with Schneider USA’s Stent Division and as an Advanced Project Engineer with 3M Medical Products Division. James received a B.S. in Industrial Engineering from Iowa State University.
Dr Boag has more than 15 years-experience working in the life sciences sector and has served in her current role as Director of Business Development at Global Kinetics since September 2018. Previously, Joanne worked at an ASX-listed diagnostic company and medical research institutions, where she led successful outcomes in research innovation and commercialisation and was responsible for the strategic management of intellectual property portfolios. Joanne is a Registered Australian Patent Attorney and has a PhD in molecular biology from the University of Western Australia.
Dr Umer is the Head of Product Development leading all software and hardware new product development and sustaining engineering. Over the past 15 years Muhammad has held product leadership roles in digital health, diagnostics, and medical device industries. Muhammad holds a PhD in Computer Science from University of Melbourne and combines his research and industry experience to lead engineering teams in building novel medical technology. Prior to joining Global Kinetics, Muhammad has held the roles of Head of Digital and eHealth at Australian Clinical Labs and Head of Software Development and Chief Software Architect at dorsaVi, an ASX listed biotechnology company focused on developing innovative motion analysis sensor technology.